{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T08:38:53Z","timestamp":1793176733353,"version":"4.5.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,2,22]],"date-time":"2020-02-22T00:00:00Z","timestamp":1582329600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program","doi-asserted-by":"publisher","award":["#2016YFC0903400"],"award-info":[{"award-number":["#2016YFC0903400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["#81520108007"],"award-info":[{"award-number":["#81520108007"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["#81770869"],"award-info":[{"award-number":["#81770869"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shandong Province Key Research and Development Program","award":["#2018CXGC1207"],"award-info":[{"award-number":["#2018CXGC1207"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Serum CA72-4 levels are elevated in some gout patients but this has not been comprehensively described. The present study profiled serum CA72-4 expression in gout patients and verified the hypothesis that CA72-4 is a predictor of future flares in a prospective gout cohort.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>To profile CA72-4 expression, a cross-sectional study was conducted in subjects with gouty arthritis, asymptomatic hyperuricaemia, four major arthritis types (OA, RA, SpA, septic arthritis) and healthy controls. A prospective gout cohort study was initiated to test the value of CA72-4 for predicting gout flares. During a 6-month follow-up, gout flares, CA72-4 levels and other gout-related clinical variables were observed at 1, 3 and 6\u2009months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>CA72-4 was highly expressed in patients with gouty arthritis [median (interquartile range) 4.55 (1.56, 32.64) U\/ml] compared with hyperuricaemia patients [1.47 (0.87, 3.29) U\/ml], healthy subjects [1.59 (0.99, 3.39) U\/ml] and other arthritis patients [septic arthritis, 1.38 (0.99, 2.66) U\/ml; RA, 1.58 (0.95, 3.37) U\/ml; SpA, 1.56 (0.98, 2.85) U\/ml; OA, 1.54 (0.94, 3.34) U\/ml; P\u2009&amp;lt;\u20090.001, respectively]. Gout patients with frequent flares (twice or more in the last year) had higher CA72-4 levels than patients with fewer flares (fewer than twice in the last year). High CA72-4 level (&amp;gt;6.9\u2009U\/ml) was the strongest predictor of gout flares (hazard ratio\u2009=\u20093.889). Prophylactic colchicine was effective, especially for patients with high CA72-4 levels (P\u2009=\u20090.014).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>CA72-4 levels were upregulated in gout patients who experienced frequent flares and CA72-4 was a useful biomarker to predict future flares.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa046","type":"journal-article","created":{"date-parts":[[2020,1,21]],"date-time":"2020-01-21T20:10:11Z","timestamp":1579637411000},"page":"2872-2880","source":"Crossref","is-referenced-by-count":18,"title":["Serum CA72-4 is specifically elevated in gout patients and predicts flares"],"prefix":"10.1093","volume":"59","author":[{"given":"Xueshan","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabology, The Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingshu","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Rheumatology & Clinical Immunology, the Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"He","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabology, The Affiliated Hospital of Qingdao University"},{"name":"Shandong Provincial Key Laboratory of Metabolic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, China"},{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhua","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Cui","sequence":"additional","affiliation":[{"name":"Shandong Provincial Key Laboratory of Metabolic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Wang","sequence":"additional","affiliation":[{"name":"Shandong Provincial Key Laboratory of Metabolic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wan","sequence":"additional","affiliation":[{"name":"Department of Mathematics and Statistics, Lancaster University, Lancaster, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabology, The Affiliated Hospital of Qingdao University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinde","family":"Li","sequence":"additional","affiliation":[{"name":"Shandong Provincial Key Laboratory of Metabolic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailong","family":"Li","sequence":"additional","affiliation":[{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjiang","family":"Wu","sequence":"additional","affiliation":[{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changgui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabology, The Affiliated Hospital of Qingdao University"},{"name":"Shandong Provincial Key Laboratory of Metabolic Diseases, The Affiliated Hospital of Qingdao University, Qingdao, China"},{"name":"Institute of Metabolic Diseases, Qingdao University, Qingdao, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,2,22]]},"reference":[{"key":"2020092423560309000_keaa046-B1","first-page":"831","article-title":"Diagnosis, treatment, and prevention of gout","volume":"90","author":"Hainer","year":"2014","journal-title":"Am Fam Physician"},{"key":"2020092423560309000_keaa046-B2","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/jama.1994.03510280064034","article-title":"Gout without hyperuricemia","volume":"271","author":"McCarty","year":"1994","journal-title":"JAMA"},{"key":"2020092423560309000_keaa046-B3","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.celrep.2017.02.004","article-title":"\u03b2-Hydroxybutyrate deactivates neutrophil NLRP3 inflammasome to relieve gout flares","volume":"18","author":"Goldberg","year":"2017","journal-title":"Cell Rep"},{"key":"2020092423560309000_keaa046-B4","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/nrd.2018.97","article-title":"Targeting the NLRP3 inflammasome in inflammatory diseases","volume":"17","author":"Mangan","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"2020092423560309000_keaa046-B5","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1136\/annrheumdis-2011-201215","article-title":"Purine-rich foods intake and recurrent gout attacks","volume":"71","author":"Zhang","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2020092423560309000_keaa046-B6","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1073\/pnas.78.5.3199","article-title":"A spectrum of monoclonal antibodies reactive with human mammary tumor cells","volume":"78","author":"Colcher","year":"1981","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020092423560309000_keaa046-B7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/ijc.2910290509","article-title":"A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor-associated antigen in human mammary carcinoma cell populations","volume":"29","author":"Nuti","year":"1982","journal-title":"Int J Cancer"},{"key":"2020092423560309000_keaa046-B8","first-page":"850","article-title":"Analysis of a human tumor-associated glycoprotein (TAG-72) identified by monoclonal antibody B72.3","volume":"46","author":"Johnson","year":"1986","journal-title":"Cancer Res"},{"key":"2020092423560309000_keaa046-B9","first-page":"3118","article-title":"Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3","volume":"46","author":"Thor","year":"1986","journal-title":"Cancer Res"},{"key":"2020092423560309000_keaa046-B10","first-page":"3649","article-title":"Cancer antigen 72-4 for the monitoring of advanced tumors of the gastrointestinal tract, lung, breast and ovaries","volume":"37","author":"Mariampillai","year":"2017","journal-title":"Anticancer Res"},{"key":"2020092423560309000_keaa046-B11","first-page":"446","article-title":"Tumor markers in pancreatic cancer\u2013current concepts","volume":"36","author":"Schmiegel","year":"1989","journal-title":"Hepatogastroenterology"},{"key":"2020092423560309000_keaa046-B12","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.1515\/cclm-2017-0399","article-title":"An abnormal elevation of serum CA72-4 due to taking colchicine","volume":"56","author":"Zhao","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"2020092423560309000_keaa046-B13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/bs.pmbts.2018.12.005","article-title":"Increased serum CA724 levels in patients suffering gout vs cancers","volume":"162","author":"Zhang","year":"2019","journal-title":"Prog Mol Biol Transl"},{"key":"2020092423560309000_keaa046-B14","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1136\/annrheumdis-2015-208237","article-title":"2015 Gout classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"74","author":"Neogi","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2020092423560309000_keaa046-B15","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 rheumatoid arthritis classification criteria an American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"key":"2020092423560309000_keaa046-B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ard.2008.104018","article-title":"The Assessment of SpondyloArthritis International Society (ASAS) handbook: a guide to assess spondyloarthritis","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2020092423560309000_keaa046-B17","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1002\/art.1780331101","article-title":"The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand","volume":"33","author":"Altman","year":"1990","journal-title":"Arthritis Rheum"},{"key":"2020092423560309000_keaa046-B18","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.1780290816","article-title":"Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association","volume":"29","author":"Altman","year":"1986","journal-title":"Arthritis Rheum"},{"key":"2020092423560309000_keaa046-B19","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken"},{"key":"2020092423560309000_keaa046-B20","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res (Hoboken"},{"key":"2020092423560309000_keaa046-B21","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1016\/S0140-6736(16)00346-9","volume":"388","author":"Dalbeth","year":"2016","journal-title":". Gout. Lancet"},{"key":"2020092423560309000_keaa046-B22","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13075-019-1918-7","article-title":"Gout, flares, and allopurinol use: a population-based study","volume":"21","author":"Proudman","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2020092423560309000_keaa046-B23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/00006676-199411000-00002","article-title":"Serological pancreatic tumor markers and the MUC1 apomucin","volume":"9","author":"Ho","year":"1994","journal-title":"Pancreas"},{"key":"2020092423560309000_keaa046-B24","first-page":"4885","article-title":"Characterization of the shed form of the human tumor-associated glycoprotein (TAG-72) from serous effusions of patients with different types of carcinomas","volume":"50","author":"Katari","year":"1990","journal-title":"Cancer Res"},{"key":"2020092423560309000_keaa046-B25","doi-asserted-by":"crossref","first-page":"49565","DOI":"10.18632\/oncotarget.10391","article-title":"Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer","volume":"7","author":"Liang","year":"2016","journal-title":"Oncotarget"},{"key":"2020092423560309000_keaa046-B26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1742-1241.2007.01614.x","article-title":"CA 72-4 levels in patients with type 2 diabetes mellitus","volume":"64","author":"Demirci","year":"2010","journal-title":"Int J Clin Pract"},{"key":"2020092423560309000_keaa046-B27","first-page":"2311","article-title":"CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers","volume":"22","author":"Carpelan-Holmstrom","year":"2002","journal-title":"Anticancer Res"},{"key":"2020092423560309000_keaa046-B28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/bs.pmbts.2018.12.002","article-title":"Glycan-based biomarkers for diagnosis of cancers and other diseases: past, present, and future","volume":"162","author":"Hu","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"2020092423560309000_keaa046-B29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/tan.12900","article-title":"Tumor-associated antigens: tn antigen, sTn antigen, and T antigen","volume":"88","author":"Fu","year":"2016","journal-title":"HLA"},{"key":"2020092423560309000_keaa046-B30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1146\/annurev-pathol-012414-040438","article-title":"Protein glycosylation in cancer","volume":"10","author":"Stowell","year":"2015","journal-title":"Annu Rev Pathol"},{"key":"2020092423560309000_keaa046-B31","first-page":"S114","article-title":"Tumor markers in familial Mediterranean fever and their correlation with the frequency of attacks","volume":"26(4 Suppl 50","author":"Balaban","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2020092423560309000_keaa046-B32","first-page":"549","article-title":"Gout\u2013current diagnosis and treatment","volume":"106","author":"Tausche","year":"2009","journal-title":"Dtsch Arztebl Int"},{"key":"2020092423560309000_keaa046-B33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/annrheumdis-2017-212365","article-title":"Performance characteristics of rheumatoid factor and anti-cyclic citrullinated peptide antibody assays may impact ACR\/EULAR classification of rheumatoid arthritis","volume":"77","author":"Van Hoovels","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2020092423560309000_keaa046-B34","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J Rheumatol"},{"key":"2020092423560309000_keaa046-B35","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice. Gout","volume":"364","author":"Neogi","year":"2011","journal-title":"N Engl J Med"},{"key":"2020092423560309000_keaa046-B36","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1002\/acr.22855","article-title":"Association of serum uric acid and disease duration with frequent gout attacks: a case-control study","volume":"68","author":"Abhishek","year":"2016","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2020092423560309000_keaa046-B37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"2020092423560309000_keaa046-B38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.psyneuen.2013.11.006","article-title":"Chronic exposure to exogenous glucocorticoids primes microglia to pro-inflammatory stimuli and induces NLRP3 mRNA in the hippocampus","volume":"40","author":"Frank","year":"2014","journal-title":"Psychoneuroendocrinology"},{"key":"2020092423560309000_keaa046-B39","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/ni.1935","article-title":"Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1\u03b2 in type 2 diabetes","volume":"11","author":"Masters","year":"2010","journal-title":"Nat Immunol"},{"key":"2020092423560309000_keaa046-B40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.15537\/smj.2017.2.15649","article-title":"The serum levels of tumor marker CA19-9, CEA, CA72-4, and NSE in type 2 diabetes without malignancy and the relations to the metabolic control","volume":"38","author":"Shang","year":"2017","journal-title":"Saudi Med J"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/10\/2872\/33790173\/keaa046.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/59\/10\/2872\/33790173\/keaa046.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T04:02:22Z","timestamp":1601006542000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/59\/10\/2872\/5748306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,22]]},"references-count":40,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,2,22]]},"published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa046","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,10]]},"published":{"date-parts":[[2020,2,22]]}}}